A non-opioid based target has been found to alleviate chronic touch pain and spontaneous pain in mice. Researchers at the Medical College of Wisconsin (MCW) discovered that blocking transient receptor potential canonical 5 (TRPC5) activity reversed touch pain in mouse models of sickle cell disease, migraine, chemotherapy-related pain, and surgical pain.